CD8A and type 1 diabetes mellitus: Recently, daily treatment of new-onset T1D patients for 48 weeks with baricitinib, a JAK1 and JAK2 inhibitor, resulted in preserved beta cell function, assessed by mixed-meal tests, reduced glycemic variability, and proportion of circulating memory effector CD8 T cells [54].